Trilaciclib combined with sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC): Updated phase 2 safety and efficacy results

被引：0
|
作者：
Seneviratne, Lasika C.
Harnden, Kathleen Kiernan
Blau, Sibel
Danso, Michael A.
Berz, David
Guaqueta, Delia Constanza
Schwerkoske, John F.
O'Shaughnessy, Joyce
Patt, Debra A.
Bardia, Aditya
McCann, Kelly Elizabeth
Beelen, Andrew Paul
Zhang, Jingshan
Yi, John S.
Hurvitz, Sara A.
Mardones, Mabel Alejandra
机构：
[1] Los Angeles Canc Network, Los Angeles, CA USA
[2] Inova Schar Canc Inst, Fairfax, VA USA
[3] Northwest Med Specialties, Puyallup, WA USA
[4] Virginia Oncol Associates, Norfolk, VA USA
[5] Virginia Oncol Associates, Virginia Beach, VA USA
[6] Valkyrie Clin Trials Inc, Los Angeles, CA USA
[7] Mem Reg Hosp, Hollywood, FL USA
[8] Minnesota Oncol Hematol PA, Woodbury, MN USA
[9] Texas Oncol, Baylor Charles A Sammons Canc Ctr, Dallas, TX USA
[10] Texas Oncol, US Oncol Network, Austin, TX USA
[11] Univ Calif Los Angeles, David Geffen Sch Med, Div Hematol Oncol, Los Angeles, CA 90095 USA
[12] Jonsson Comprehens Canc Ctr, Los Angeles, CA 90034 USA
[13] Beverly Hills Canc Care, Los Angeles, CA USA
[14] G1 Therapeut Inc, Res Triangle Pk, NC USA
[15] Univ Washington Sch Med, Seattle, WA USA
[16] Fred Hutchinson Canc Ctr, Seattle, WA USA
[17] Rocky Mt Canc Ctr, Sarah Cannon Res Inst, Denver, CO USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1091
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Post-progression therapy outcomes in patients (pts) from the phase 3 ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC)
    Cortes, Javier
    Bardia, Aditya
    Loirat, Delphine
    Tolaney, Sara M.
    Punie, Kevin
    Oliveira, Mafalda
    Hurvitz, Sara A.
    Brufsky, Adam
    Sardesai, Sagar
    Kalinsky, Kevin M.
    Traina, Tiffany
    Hamilton, Erika
    O'Shaughnessy, Joyce
    Dieras, Veronique
    Carey, Lisa A.
    Piccart, Martine
    Loibl, Sibylle
    Rugo, Hope S.
    Zhu, Yanni
    Phan, See
    Gianni, Luca
    CANCER RESEARCH, 2022, 82 (04)
  • [22] Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer
    Rugo, Hope S.
    Tolaney, Sara M.
    Loirat, Delphine
    Punie, Kevin
    Bardia, Aditya
    Hurvitz, Sara A.
    O'Shaughnessy, Joyce
    Cortes, Javier
    Dieras, Veronique
    Carey, Lisa A.
    Gianni, Luca
    Piccart, Martine J.
    Loibl, Sibylle
    Goldenberg, David M.
    Hong, Quan
    Olivo, Martin
    Itri, Loretta M.
    Kalinsky, Kevin
    NPJ BREAST CANCER, 2022, 8 (01)
  • [23] Sacituzumab-govitecan in metastatic triple-negative breast cancer: a multicenter effectiveness and safety study
    Carrion-Madronal, Isabel Maria
    Diaz-Acedo, Rocio
    Lora-Escobar, Santiago Jose
    Naranjo-Llamas, Eloisa
    Jaramillo-Ruiz, Didiana
    Artacho-Criado, Silvia
    Prado-Mel, Elena
    FUTURE ONCOLOGY, 2024, 20 (33) : 2565 - 2572
  • [24] Efficacy and safety of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer (mTNBC) by baseline HER2 expression level: Subgroup analysis from a phase IIb trial
    Xu, B.
    Ma, F.
    Wang, S.
    Tong, Z.
    Li, W.
    Wu, X.
    Wang, X.
    Sun, T.
    Pan, Y.
    Yao, H.
    Wang, X.
    Luo, T.
    Yang, J.
    Zeng, X.
    Zhao, W.
    Cong, X. J.
    Wang, N.
    Xu, C.
    Chen, J. J.
    ANNALS OF ONCOLOGY, 2022, 33 : S1438 - S1438
  • [25] Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
    Bardia, A.
    Mayer, I. A.
    Vahdat, L. T.
    Tolaney, S. M.
    Isakoff, S. J.
    Diamond, J. R.
    O'Shaughnessy, J.
    Moroose, R. L.
    Santin, A. D.
    Abramson, V. G.
    Shah, N. C.
    Rugo, H. S.
    Goldenberg, D. M.
    Sweidan, A. M.
    Iannone, R.
    Washkowitz, S.
    Sharkey, R. M.
    Wegener, W. A.
    Kalinsky, K.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (08): : 741 - 751
  • [26] Sacituzumab govitecan in Japanese patients with metastatic triple-negative breast cancer: phase 2 results of ASCENT J02
    Naito, Y.
    Nakamura, S.
    Kawaguchi, N.
    Ishida, T.
    Nakayama, T.
    Yamamoto, Y.
    Masuda, N.
    Matsumoto, K.
    Kogawa, T.
    Sudo, K.
    Shimomura, A.
    Lai, C.
    Zhang, D.
    Iwahori, Y.
    Gary, D.
    Huynh, D.
    Iwata, H.
    ANNALS OF ONCOLOGY, 2024, 35 : S1326 - S1326
  • [27] Metastatic triple-negative Breast Cancer (mTNBC) - Second-line Therapy mTNBC: Sacituzumab Govitecan with high Effectiveness even in HER2-low
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 (7-8) : 343 - 343
  • [28] Sacituzumab Govitecan-hziy in Triple-Negative Breast Cancer
    Ozaki, Yukinori
    Masuda, Jun
    Takano, Toshimi
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (24): : 2382 - 2382
  • [29] Sacituzumab govitecan-hziy for triple-negative breast cancer
    Stirrups, Robert
    LANCET ONCOLOGY, 2019, 20 (04): : E194 - E194
  • [30] Real-world outcomes in patients (pts) with metastatic triple-negative breast cancer (mTNBC) treated with sacituzumab govitecan (SG) in 2L+in the United States (US)
    Kalinsky, Kevin
    Spring, Laura
    Yam, Clinton
    Taylor, Aliki
    Sjekloca, Nikoleta
    Kaushiva, Alpana
    Lai, Catherine
    Ntalla, Ioanna
    Nanda, Rita
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345